Gen-Plus GmbH & Co. KG was founded in 1999 to serve the pharmaceutical industry with the focus on R&D services, mainly in new technologies for medicinal products. Initially, these research activities were performed as a 100% subsidiary of Ratiopharm.
In June 2015 the company was acquired by Dr. Markus Dachtler, and a privately-owned independent company was working for various pharmaceutical companies as contractual research, development and manufacturing organization. We continuously invested in our innovative laboratory to provide our customers with a wide range of attractive development opportunities.
In 2022, the company was acquired by the Conscio Group and has been operating as a full service provider for pharmaceutical innovation from the product idea to the final drug product. We focus on feasibility studies, proof of concepts, formulation and process development, process scale up as well manufacturing and release of IMPs and validation batches in the area of solids, semi-solids, non-sterile liquids, transdermal systems, orodispersible thin films and personalized medicine via 2D and 3D printed as well as innovative formulations and capabilities for processing high potent APIs as well as narcotics (controlled substances).